ENDONUCLEASEN

European patent · EP2814954 · In force

Register entry

Publication number
EP2814954
Application number
EP13705249
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 18, 2013
Published
Dec 24, 2014
Granted
Apr 5, 2017
Protection ends at the latest
Feb 17, 2033
Next annual fee due
Feb 28, 2027
IPC classes
C12N 9/22 (2006.01)
C12N 9/99 (2006.01)
C12Q 1/68 (2006.01)
Priority
GB 201202768 17.02.2012
GB 201216029 07.09.2012
PCT application
PCT/GB2013/050387 18.02.2013
PCT publication
WO2013/121228 22.08.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  3. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  4. Mar 6, 2023

    Change

    Published in Swissreg on 06.03.2023

  5. Apr 5, 2017

    Granted

    Published in Swissreg on 05.04.2017

Parties

Holder

Biotec Pharmacon ASA

Sykehusveien 23, 9294 Tromsø, NO

Inventor

LANES, Olav

N-9007 Tromsø, NO

HAVDALEN, Linda

N-9020 Tromsdalen, NO

SOLSTAD, Terese

N-9100 Kvaløysletta, NO

LORENTZEN, Marit

N-9022 Krokelvdalen, NO

LEIROS,Ingar

N-9017 Tromso, NO

HELLAND,Ronny

N-9020 Tromsdalen, NO

ALTERMARK, Bjorn

N-9014 Tromso, NO

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.